Serum Vitamin D Status and Breast Cancer Risk by Receptor Status: A Systematic Review

Overview

Journal Nutr Cancer

Publisher Routledge

Specialties Nutritional Sciences
Oncology

Date 2018 May 22

PMID 29781719

Citations 11

Authors

Jessica L Tommie

Susan M Pinney

Laurie A Nommsen-Rivers

Affiliations

Soon will be listed here.

Abstract

Background: The association between vitamin D status and breast cancer risk is equivocal. No systematic reviews or meta-analyses have examined this association stratified by receptor status. Our objective is to conduct a systematic review to answer the question, "Is there a relationship between lower serum/plasma vitamin D levels and increased risk of triple negative breast cancer (TNBC) specifically?"

Methods: We systematically searched Embase and PubMed databases for published original research studies examining the risk of a breast cancer diagnosis according to vitamin D status. We excluded studies that did not provide risk estimates stratified by receptor status.

Results: Fourteen studies met our criteria, including case-control, nested case-control, and case-series studies, reflecting the cumulative results of 13,135 breast cancer cases. When grouped by relevancy to TNBC, the proportion of analyses across all study types showing a significant association between vitamin D status and breast cancer diagnosis was 37% for non-TNBC analyses, 48% for analyses that included some TNBC cases, and 88% for TNBC analyses.

Conclusions: Our results suggest that low vitamin D status may particularly increase the risk of TNBC, although more research is needed to determine if this association is causative. Women should be routinely screened for 25(OH)D deficiency.

Citing Articles

Personal history of irradiation and risk of breast cancer: A Mendelian randomisation study.

Liu Y, Liu Z, Chen J, Liang M, Cai C, Zou F J Glob Health. 2024; 14:04106.

PMID: 39391896 PMC: 11467774. DOI: 10.7189/jogh.14.04106.

Causes and Risk Factors of Breast Cancer, What Do We Know for Sure? An Evidence Synthesis of Systematic Reviews and Meta-Analyses.

Loyland B, Sandbekken I, Grov E, Utne I Cancers (Basel). 2024; 16(8).

PMID: 38672665 PMC: 11049405. DOI: 10.3390/cancers16081583.

Vitamin K2 enhances the tumor suppressive effects of 1,25(OH)D in triple negative breast cancer cells.

Narvaez C, Bak M, Salman N, Welsh J J Steroid Biochem Mol Biol. 2023; 231:106307.

PMID: 37030416 PMC: 10752295. DOI: 10.1016/j.jsbmb.2023.106307.

Prevalence and Relevance of Vitamin D Deficiency in Newly Diagnosed Breast Cancer Patients: A Pilot Study.

Zemlin C, Altmayer L, Stuhlert C, Schleicher J, Wormann C, Lang M Nutrients. 2023; 15(6).

PMID: 36986179 PMC: 10056197. DOI: 10.3390/nu15061450.

Vitamin D as a Potential Preventive Agent For Young Women's Breast Cancer.

Bernhardt S, Borges V, Schedin P Cancer Prev Res (Phila). 2021; 14(9):825-838.

PMID: 34244152 PMC: 8937000. DOI: 10.1158/1940-6207.CAPR-21-0114.

References

Janssen M, Wielders J, Bekker C, Boesten L, Buijs M, Heijboer A . Multicenter comparison study of current methods to measure 25-hydroxyvitamin D in serum. Steroids. 2012; 77(13):1366-72. DOI: 10.1016/j.steroids.2012.07.013. View

Wang D, Velez de-la-Paz O, Zhai J, Liu D . Serum 25-hydroxyvitamin D and breast cancer risk: a meta-analysis of prospective studies. Tumour Biol. 2013; 34(6):3509-17. DOI: 10.1007/s13277-013-0929-2. View

Kim Y, Je Y . Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysis. Br J Cancer. 2014; 110(11):2772-84. PMC: 4037823. DOI: 10.1038/bjc.2014.175. View

Forrest K, Stuhldreher W . Prevalence and correlates of vitamin D deficiency in US adults. Nutr Res. 2011; 31(1):48-54. DOI: 10.1016/j.nutres.2010.12.001. View

Peairs K, Choi Y, Stewart R, Sateia H . Screening for breast cancer. Semin Oncol. 2017; 44(1):60-72. DOI: 10.1053/j.seminoncol.2017.02.004. View

Shirazi L, Almquist M, Borgquist S, Malm J, Manjer J . Serum vitamin D (25OHD3) levels and the risk of different subtypes of breast cancer: A nested case-control study. Breast. 2016; 28:184-90. DOI: 10.1016/j.breast.2016.06.002. View

Cheang M, Martin M, Nielsen T, Prat A, Voduc D, Rodriguez-Lescure A . Defining breast cancer intrinsic subtypes by quantitative receptor expression. Oncologist. 2015; 20(5):474-82. PMC: 4425383. DOI: 10.1634/theoncologist.2014-0372. View

Prat A, Pineda E, Adamo B, Galvan P, Fernandez A, Gaba L . Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015; 24 Suppl 2:S26-35. DOI: 10.1016/j.breast.2015.07.008. View

Kuhn T, Kaaks R, Becker S, Eomois P, Clavel-Chapelon F, Kvaskoff M . Plasma 25-hydroxyvitamin D and the risk of breast cancer in the European prospective investigation into cancer and nutrition: a nested case-control study. Int J Cancer. 2013; 133(7):1689-700. DOI: 10.1002/ijc.28172. View

10.

Eliassen A, Spiegelman D, Hollis B, Horst R, Willett W, Hankinson S . Plasma 25-hydroxyvitamin D and risk of breast cancer in the Nurses' Health Study II. Breast Cancer Res. 2011; 13(3):R50. PMC: 3218936. DOI: 10.1186/bcr2880. View

11.

Yao S, Hong C, McCann S, Zirpoli G, Quan L, Gong Z . Combined effects of circulating levels of 25-hydroxyvitamin d and Th1 and th2 cytokines on breast cancer estrogen receptor status. Cancers (Basel). 2014; 6(1):211-25. PMC: 3980607. DOI: 10.3390/cancers6010211. View

12.

Rejnmark L, Tietze A, Vestergaard P, Buhl L, Lehbrink M, Heickendorff L . Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev. 2009; 18(10):2655-60. DOI: 10.1158/1055-9965.EPI-09-0531. View

13.

McCullough M, Stevens V, Patel R, Jacobs E, Bain E, Horst R . Serum 25-hydroxyvitamin D concentrations and postmenopausal breast cancer risk: a nested case control study in the Cancer Prevention Study-II Nutrition Cohort. Breast Cancer Res. 2009; 11(4):R64. PMC: 2750126. DOI: 10.1186/bcr2356. View

14.

Yao S, Sucheston L, Millen A, Johnson C, Trump D, Nesline M . Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: a case-control and a case-series study. PLoS One. 2011; 6(2):e17251. PMC: 3046139. DOI: 10.1371/journal.pone.0017251. View

15.

Lopes N, Paredes J, Costa J, Ylstra B, Schmitt F . Vitamin D and the mammary gland: a review on its role in normal development and breast cancer. Breast Cancer Res. 2012; 14(3):211. PMC: 3446331. DOI: 10.1186/bcr3178. View

16.

Eliassen A, Warner E, Rosner B, Collins L, Beck A, Quintana L . Plasma 25-Hydroxyvitamin D and Risk of Breast Cancer in Women Followed over 20 Years. Cancer Res. 2016; 76(18):5423-30. PMC: 5026605. DOI: 10.1158/0008-5472.CAN-16-0353. View

17.

Jamdade V, Sethi N, Mundhe N, Kumar P, Lahkar M, Sinha N . Therapeutic targets of triple-negative breast cancer: a review. Br J Pharmacol. 2015; 172(17):4228-37. PMC: 4556464. DOI: 10.1111/bph.13211. View

18.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009; 6(7):e1000100. PMC: 2707010. DOI: 10.1371/journal.pmed.1000100. View

19.

Enko D, Fridrich L, Rezanka E, Stolba R, Ernst J, Wendler I . 25-hydroxy-Vitamin D status: limitations in comparison and clinical interpretation of serum-levels across different assay methods. Clin Lab. 2014; 60(9):1541-50. DOI: 10.7754/clin.lab.2014.131114. View

20.

So J, Suh N . Targeting cancer stem cells in solid tumors by vitamin D. J Steroid Biochem Mol Biol. 2014; 148:79-85. PMC: 4361233. DOI: 10.1016/j.jsbmb.2014.10.007. View